Urinary Bladder Cancer in Dogs: A Promising Model for Advancing Human Urothelial Carcinoma Research?
DOI:
https://doi.org/10.46419/cvj.57.5.7Keywords:
urothelial carcinoma, transitional carcinoma, translational models, comparative oncology, canineAbstract
Dogs are widely recognised as valuable models in comparative oncology because they develop cancer spontaneously, have shorter lifespans, and share significant biological and clinical similarities with human tumours. The objective of this review was to assess the relevance of canine urothelial carcinoma (UC) as a translational model for human bladder cancer by comparing epidemiological patterns, molecular alterations, and immunological features across species. Urothelial carcinoma is of particular interest due to its aggressive nature and high mortality rates. In dogs, invasive forms of UC are more common, underscoring the relevance of this species for modelling human disease. While advanced age and exposure to environmental carcinogens are shared risk factors, notable epidemiological differences exist, including a higher prevalence in female dogs than in male humans. Molecularly, canine and human UCs share tumour subtypes and dysregulation of key oncogenic pathways, such as p53/p63, RTK/RAS/MAPK, PI3K/AKT/mTOR, and CDKN2A/CDK4, despite distinct initiating genetic events. These alterations converge on pathways controlling proliferation, survival, and immune evasion. Shared overexpression of therapeutic targets and similar immune checkpoint mechanisms further support the translational value of the canine model. Collectively, these features reinforce the utility of dogs in advancing biological understanding and therapeutic development for urothelial carcinoma in both veterinary and human medicine.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.